TP53 and myelodysplastic syndrome: A registration phase III clinical trial comparing AZA + APR-246 with AZA in monotherapy (NCT03745716), as well as a phase II study evaluating the same combination as maintenance therapy after allo-HSCT (NCT03931291) in TP53 mutated AML/MDS patients are ongoing.